AIMD Ainos: Enterprise Value-to-Revenue Multiple

Public company logo of Ainos (AIMD)

Ainos, Inc. generates revenue through the sale of rapid tests and AI gadgets for respiratory biomarker analysis. The EV/Sales market multiple reflects the business valuation trend, with the metric currently fixed at 33138.46. Ainos, Inc. mitigates risks through software licensing and expansion in the US. Meanwhile, production automation and data analysis algorithms minimize the need for a large workforce.

AIMD Ainos Corporation: Company Value to Revenue in the range 11/23/2025 - 11/20/2026

AIMD (Ainos, Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental company valuation:Ainos, Inc.
Original product of Ainos Corporation

This indicator determines the market value of the business, accounting for net debt relative to the volume of generated sales, to identify whether the asset is fundamentally overvalued or undervalued. An analysis of enterprise value via EV/Sales allows for a comparison of Ainos, Inc. (AIMD) total capital with the effectiveness of its strategy to implement portable diagnostic systems and remote health monitoring devices in the home sector.

Direct competitors

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|prenetics.com - EV/Sales Multiple|Insight Molecular Diagnostics, Inc. (IMDX) - Company Value to Revenue|TRIB: EV/Sales Multiple|ProPhase - Business Value to Revenue|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue